What non‑benzodiazepine pharmacologic options are appropriate for a patient with severe anxiety who wishes to avoid benzodiazepines?

Non-Benzodiazepine Medications for Extreme Anxiety

For a patient with severe anxiety who wishes to avoid benzodiazepines, start with escitalopram 10 mg daily or sertraline 50 mg daily as first-line pharmacotherapy, combined with individual cognitive-behavioral therapy (CBT) for superior outcomes. 1, 2

First-Line Pharmacologic Options

SSRIs (Preferred Initial Agents)

• Escitalopram and sertraline are the top-tier first-line agents due to their established efficacy, favorable side effect profiles, lowest potential for drug-drug interactions, and smallest discontinuation-symptom burden compared to other SSRIs. 1, 2

• All SSRIs as a class demonstrate robust efficacy for anxiety disorders with moderate-to-high strength of evidence, showing a number needed to treat (NNT) of approximately 4.7—meaning roughly one in five patients will benefit beyond placebo. 1, 2

• Expected timeline for response: Statistically significant improvement may begin by week 2, clinically meaningful improvement is typically evident by week 6, and maximal therapeutic benefit is generally reached by week 12 or later. 1

• Starting doses and titration:

  • Escitalopram: Start 5-10 mg daily, increase by 5-10 mg increments every 1-2 weeks, target 10-20 mg/day 1
  • Sertraline: Start 25-50 mg daily, increase by 25-50 mg increments every 1-2 weeks, target 50-200 mg/day 1

• Common side effects include nausea (most frequent cause of discontinuation), sexual dysfunction, headache, insomnia, dry mouth, diarrhea, heartburn, somnolence, dizziness, and vivid dreams; most adverse effects emerge within the first few weeks and typically resolve with continued treatment. 1, 2

• Critical warning: All SSRIs carry a boxed warning for suicidal thinking and behavior in individuals up to age 24, with pooled absolute rates of 1% versus 0.2% for placebo; close monitoring is essential, especially in the first months and following dose adjustments. 1

SNRIs (Equally Effective Alternative)

• Venlafaxine extended-release (75-225 mg/day) and duloxetine (60-120 mg/day) are effective alternatives when SSRIs are ineffective or not tolerated, with efficacy comparable to SSRIs (NNT = 4.94 for venlafaxine). 1, 2, 3, 4, 5, 6

• Venlafaxine requires blood pressure monitoring due to risk of sustained hypertension. 1, 2

• Duloxetine has additional benefits for patients with comorbid pain conditions. 1

• Venlafaxine carries a notable discontinuation-syndrome risk; when stopping, taper gradually over 10-14 days or longer. 1

Second-Line Pharmacologic Options

Pregabalin/Gabapentin

• Pregabalin is the anticonvulsant with the most robust level of evidence in GAD, rapidly reducing anxiety with a safe side effect profile and low potential for abuse; it can be considered when first-line treatments are ineffective or not tolerated, particularly for patients with comorbid pain conditions. 1, 3

Buspirone

• Buspirone is FDA-approved for GAD and has relatively good evidence of efficacy, though it does not exhibit cross-tolerance with benzodiazepines and will not block withdrawal syndrome from sedative/hypnotic drugs. 7, 3, 4, 6

• Buspirone can bind to central dopamine receptors, raising questions about potential dopaminergic effects (e.g., restlessness, akathisia); a syndrome of restlessness appearing shortly after initiation has been reported in some patients. 7

• Contraindication: Do not use with MAOIs or within 14 days of stopping an MAOI due to increased risk of serotonin syndrome and elevated blood pressure. 7

Quetiapine (Second-Generation Antipsychotic)

• Quetiapine has similar efficacy to SSRIs in low dosages for GAD, yet with lower overall tolerability; it is the antipsychotic of choice in GAD when other options have failed. 3, 6

• Use requires close monitoring for adverse effects such as weight gain, metabolic dysregulation, sedation, and orthostatic hypotension. 8, 3

• Caution: Combining quetiapine with benzodiazepines carries risk of oversedation and respiratory depression. 8

Essential Combination with Psychotherapy

• Adding individual CBT (12-20 sessions) to pharmacotherapy yields superior outcomes compared to either treatment alone for patients with moderate to severe anxiety, with moderate-to-high strength of evidence. 1, 2, 6

• Individual CBT is preferred over group therapy due to superior clinical effectiveness and cost-effectiveness. 1, 2

• When face-to-face CBT is unavailable or declined, self-help CBT with professional support is a viable alternative. 1, 2

• CBT should include education on anxiety, cognitive restructuring to challenge distortions, relaxation techniques, and gradual exposure when appropriate. 1

Treatment Algorithm for Severe Anxiety

1. Initial treatment: Start with escitalopram or sertraline at low doses, titrate gradually over 4-6 weeks to minimize side effects. 1, 2

2. Concurrent CBT: Refer for individual CBT immediately; do not wait for medication response. 1, 2

3. Assess response at 8-12 weeks: If inadequate response after 8-12 weeks at therapeutic doses, switch to a different SSRI or to venlafaxine XR. 1, 2

4. Second-line options: If two SSRI/SNRI trials fail, consider pregabalin or augmentation with CBT if not already implemented. 1, 3

5. Maintenance: Continue effective medication for minimum 9-12 months after achieving remission to prevent relapse. 1

Medications to Avoid

• Benzodiazepines should be reserved for short-term use only (days to a few weeks) due to risks of dependence, tolerance, cognitive impairment, and withdrawal; they are not recommended as first-line or long-term therapy for anxiety disorders. 8, 1, 2, 9

• Beta-blockers (atenolol, propranolol) are deprecated by Canadian guidelines for generalized anxiety disorder and social anxiety disorder due to lack of efficacy. 1, 2

• Tricyclic antidepressants should be avoided due to unfavorable risk-benefit profile, particularly cardiac toxicity. 1

Critical Clinical Pitfalls

• Do not abandon treatment prematurely: Full response may take 12+ weeks; allow adequate time at therapeutic doses before declaring treatment failure. 1

• Do not escalate doses too quickly: Allow 1-2 weeks between increases to assess tolerability and avoid overshooting the therapeutic window. 1

• Do not use medication alone: Combining medication with CBT provides superior outcomes; relying on medication alone is insufficient for severe anxiety. 1, 2

• Do not overlook functional impairment: Assess how anxiety interferes with work, home responsibilities, and social interactions, not just symptom scores. 1

• Monitor adherence closely: Patients with anxiety pathology commonly avoid follow-through on referrals; proactively assess and address barriers to treatment adherence. 1

Adjunctive Non-Pharmacologic Strategies

• Structured physical activity and regular cardiovascular exercise provide moderate to large reduction in anxiety symptoms. 1

• Breathing techniques, progressive muscle relaxation, grounding strategies, visualization, mindfulness, and sensory grounding techniques are useful adjuncts to primary treatment. 1

• Avoid excessive caffeine and alcohol as both can exacerbate anxiety symptoms. 1

• Sleep hygiene education can address insomnia which commonly co-occurs with anxiety. 1